<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Varga, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Virginia Steen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pulmonary complications of systemic sclerosis (SSc) are common and are the leading cause of SSc-related death. The most common pulmonary manifestations of SSc are pulmonary hypertension (PH), interstitial lung disease (ILD), and any combination thereof.</p><p>The classification, definition, risk factors, screening, and prognosis of systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH), specifically group 1 pulmonary arterial hypertension (PAH), are reviewed here. Group 2 PH and group 3 PH are discussed separately. (See  <a class="medical medical_review" href="/d/html/8258.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'General measures and supportive therapy'</a> and  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p>The evaluation and diagnosis of lung disease in SSc as well as clinical manifestations, diagnosis, and treatment of SSc-PAH are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)"</a> and  <a class="medical medical_review" href="/d/html/4368.html" rel="external">"Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)"</a> and  <a class="medical medical_review" href="/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Many different forms of pulmonary hypertension (PH) occur in systemic sclerosis (SSc). Patients with PH are classified into five groups, as shown in the table  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. SSc is most often associated with group 1 pulmonary arterial hypertension (PAH) and group 3 PH (PH due to chronic lung disease and/or chronic hypoxemia), and less commonly with group 2 PH (pulmonary <strong>venous</strong> hypertension, which is usually due to left heart disease). Due to the varied and sometimes mixed etiology underlying PH in SSc, the precise classification of the type of PH can be challenging.</p><p>When all five groups are described collectively, the term PH is used. When referring to patients in group 1, the term PAH is used (the focus of this topic). A more detailed description of the classification of PH is discussed separately. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Postdiagnostic testing and classification'</a>.)</p><p class="headingAnchor" id="H151841139"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Systemic sclerosis-associated pulmonary <strong>arterial</strong> hypertension (SSc-PAH) is defined as a mean pulmonary artery pressure (PAP) greater than 20 mmHg supine and at rest (measured by right heart catheterization [RHC]), a wedge pressure less than or equal to 15 mmHg, and a peripheral pulmonary vascular resistance ≥2 Wood units in a patient who has systemic sclerosis (SSc) without chronic hypoxemia from coexisting interstitial lung disease (ILD) [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H72705394"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc) is unknown, but estimated on average to range from 10 to 15 percent [<a href="#rid3">3-15</a>]. PAH is the leading cause of death in SSc, with two-year survival rates ranging from 64 to 89 percent [<a href="#rid12">12,16,17</a>]. In addition, a significant proportion of patients with systemic sclerosis-associated pulmonary hypertension (SSc-PAH; approximately 22 percent) are asymptomatic at diagnosis [<a href="#rid16">16,18</a>]. (See  <a class="medical medical_review" href="/d/html/7542.html" rel="external">"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>On average, 10 to 15 percent of patients with systemic sclerosis (SSc) develop pulmonary arterial hypertension (PAH) [<a href="#rid3">3-10,14,15</a>]. SSc patients who are at greatest risk for PAH are those with the following  (<a class="graphic graphic_table graphicRef93544" href="/d/graphic/93544.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Long-standing limited cutaneous SSc (lcSSc).</p><p class="bulletIndent1"><span class="glyph">●</span>Low (&lt;80 percent predicted) or progressive decline in the diffusion capacity of carbon monoxide (DLCO), and/or a high forced vital capacity (FVC)/DLCO ratio (FVC/DLCO &gt;1.6).</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP).</p><p class="bulletIndent1"><span class="glyph">●</span>Anticentromere, anti-U1-ribonuleoprotein (RNP), and nucleolar pattern antinuclear antibodies (nucleolar-ANA).</p><p class="bulletIndent1"><span class="glyph">●</span>Extensive cutaneous telangiectasia.</p><p></p><p class="headingAnchor" id="H174327834"><span class="h2">Clinical</span></p><p class="headingAnchor" id="H63163110"><span class="h3">Long-standing SSc</span><span class="headingEndMark"> — </span>Long-standing SSc has been associated with the development of PAH in several studies [<a href="#rid11">11,19-21</a>]. One meta-analysis reported longer SSc disease duration correlated positively with the development of PAH [<a href="#rid19">19</a>]. Age has also been identified as a risk factor for the development in PAH in SSc. It is thought that this may be due to an association between age and long-standing disease. A prospective observational study of 709 SSc patients reported a 22 percent increase in the risk of PAH for every 10 years after disease onset [<a href="#rid11">11</a>]. In the same study, patients &gt;60 years had a twofold greater risk of PAH compared with those &lt;60 years.</p><p class="headingAnchor" id="H63163104"><span class="h3">Limited cutaneous SSc</span><span class="headingEndMark"> — </span>Limited cutaneous SSc (LcSSc) has historically been associated with an increased risk for the development of PAH [<a href="#rid22">22</a>]. Most series of PAH in scleroderma have significantly more patients with lcSSc. However, subsequent studies have more carefully evaluated patients with the diffuse form of cutaneous SSc (dcSSc) and PAH is more frequent in this population than initially thought [<a href="#rid23">23</a>]. For example one 2008 study reported that the prevalence of PAH was similar in both SSc subsets [<a href="#rid24">24</a>]. Since dcSSc patients are more likely to have pulmonary or cardiac fibrosis, distinguishing PAH from other types of PH in these patients is challenging.</p><p>Patients with lcSSc have skin manifestation limited to the hands and frequently have prominent vascular manifestations (eg, Raynaud phenomenon and telangiectasia). The total burden of cutaneous telangiectasias, common in lcSSc, also correlates positively with the risk of PAH [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Evaluation for suspected systemic sclerosis'</a>.)</p><p class="headingAnchor" id="H63163085"><span class="h2">Abnormal pulmonary function (low diffusion)</span><span class="headingEndMark"> — </span>Low or progressive decline in the DLCO in patients with SSc is considered a risk factor for the development of PAH [<a href="#rid3">3,26-28</a>]. This was best demonstrated by a case control study of 106 patients with lcSSc with PAH who were matched to patients without PAH according to age, sex, extent of skin involvement, and disease duration [<a href="#rid26">26</a>]. Compared with controls, patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc–PAH), had a lower DLCO (52 versus 81 percent of predicted) that preceded the development of PAH by, on average, five years. In addition, the DLCO declined linearly in patients with PAH over a 10- to 15-year period but remained unchanged in the control group. Other observational studies of patients with SSc have reported a low DLCO/alveolar volume (V<sub>A</sub>) ratio (DLCO/V<sub>A</sub> &lt;70 percent) or a DLCO that is decreased disproportionately to the forced vital capacity (ie, FVC percent/DLCO percent &gt;1.6) as predictors for the development of SSc-PAH [<a href="#rid3">3,27</a>]. (See  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Pulmonary function testing'</a>.)</p><p class="headingAnchor" id="H770951024"><span class="h2">Serology</span><span class="headingEndMark"> — </span>Autoantibodies that are associated with an increased risk of SSc-PAH include anticentromere antibodies (ACA), RNP, nucleolar pattern of nucleolar-ANA, and rarely, antiphospholipid antibodies [<a href="#rid13">13,23,29-33</a>]. The absence of anti-Scl 70 (also called anti-topoisomerase I) is associated with the development of PAH [<a href="#rid26">26</a>]. By contrast, SSc patients with Scl 70 autoantibodies are more likely to have PH due to interstitial lung disease (ILD) (group 3 PH). Patients with SSc who have anti-ribonucleic acid polymerase III autoantibodies characteristically have extensive skin involvement and increased risk for scleroderma renal crisis, but uncommonly develop PAH [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H17693617"><span class="h2">Other</span><span class="headingEndMark"> — </span>Less well-established risk factors for the development of SSc-PAH include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Demographic</strong> – Large observational cohort studies report conflicting data on the impact of race on the development of SSc-PAH but do suggest that male sex is a risk factor [<a href="#rid16">16,20,22,26</a>]. In a study of SSc patients, while the frequency of PAH in males was not higher than females, males had a shorter interval between disease onset and PAH development, and were more likely to have diffuse subtype and interstitial lung disease [<a href="#rid34">34</a>]. Additionally, several studies have shown that older age at onset of disease was associated with greater risk for PAH [<a href="#rid11">11,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise-induced PH</strong> – Exercise-induced PH on right heart catheterization (RHC) and stress echocardiogram has been reported to be associated with increased risk for developing PAH in patients with SSc [<a href="#rid3">3,35</a>]. For example, in an observational study of patients with SSc in whom exercise-induced PH was identified, nearly 20 percent progressed to PAH over a three-year period [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biomarkers</strong> – Potential biomarkers for the identification of patients with SSc at risk of PAH, such as NT-proBNP and hepatocyte growth factor (HGF), are not yet validated for routine use [<a href="#rid36">36-38</a>]. Similarly, the Cochin risk prediction score that calculates the risk of PAH in SSc patients using a combination of clinical variables (age, FVC, DLCO/V<sub>A</sub>) requires validation and is not routinely used [<a href="#rid39">39</a>]. However, it is used investigationally.</p><p></p><p class="headingAnchor" id="H5"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>The high prevalence rate of pulmonary arterial hypertension (PAH), poor survival, and lack of symptoms, combined with the observation that early treatment of milder disease improves symptoms and may prolong survival, provides a rationale for screening of PAH in patients with systemic sclerosis (SSc) [<a href="#rid35">35,40,41</a>]</p><p class="headingAnchor" id="H17151427"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>While there is consensus regarding the need to screen selected patients with SSc for PAH, there is no agreed-upon best approach [<a href="#rid1">1,42,43</a>]. The most commonly used assessment tools are clinical evaluation, pulmonary function testing (PFTs), and echocardiography. The initial screening for both PAH and interstitial lung disease (ILD) in patients newly diagnosed with SSc is described separately. (See  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Evaluation for lung disease at time of SSc presentation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial visits</strong> – Most experts agree that screening should be considered at the initial visit with re-evaluation at intervals throughout the disease course [<a href="#rid1">1</a>]. In addition, most clinicians agree that routine screening with echocardiogram and/or right heart catheterization (RHC) is not practical. Consequently, screening algorithms that combine clinical, physiologic, and echocardiographic findings in high-risk SSc patients have been used to identify those in whom RHC is indicated [<a href="#rid1">1,42-46</a>]. Specific algorithm parameters vary among studies and their use is varied. The potential pitfalls of screening with echocardiography include the impact of false positive and false negative results. False-positive results may lead to unnecessary RHC and related complications, as well as unnecessary patient anxiety. False-negative results may lead to false reassurance and decreased vigilance in the clinical assessment of symptoms and signs of PAH, potentially delaying diagnosis and initiation of therapy. False positives are particularly common among patients with SSc who also have ILD [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">Our practice is the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients with SSc are screened for the signs and/or symptoms of PAH (eg, dyspnea, syncope, signs of right heart failure, loud pulmonic [P2] heart sound) at initial presentation and every visit during follow-up. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients should have a full set of PFTs (spirometry, lung volumes, and DLCO) at the initial visit and annually thereafter. If they have a normal force vitality capacity (FVC) and DLCO, we decrease the frequency of PFTs to every two years in patients with long-standing SSc (more than five years), no dyspnea or exercise intolerance, and in those with PFTs that have remained unchanged over several years (more than three years). (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We perform two-dimensional and Doppler echocardiography on the initial visit in patients with SSc who have symptoms (eg, dyspnea on exertion) or are at substantially increased risk for PAH (eg, long-standing disease, limited cutaneous SSc [lcSSc], DLCO &lt;80 percent predicted) or when other SSc-associated complications are suspected (eg, constrictive cardiomyopathy, pericardial effusion). We do not advocate routine echocardiographic PAH screening for patients with SSc who have no suggestive symptoms and have a normal DLCO. When the DLCO is decreased, we assess for concomitant restrictive disease or abnormal high-resolution computed tomography findings that might suggest interstitial lung disease as an alternate explanation for the reduced DLCO. If systemic sclerosis-associated pulmonary arterial hypertension (SSc–PAH) is suspected based on the clinical features, pulmonary function tests, and echocardiogram, then an RHC is performed. (See <a class="local">'Risk factors'</a> above and  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Pulmonary function testing'</a> and  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Imaging'</a> and  <a class="medical medical_review" href="/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Evaluation for suspected systemic sclerosis'</a>.)</p><p></p><p class="bulletIndent1">Support for this general approach is based upon data from large observational cohort series [<a href="#rid7">7,8,44,48,49</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One prospective international multicenter study (Early, Simple, and Reliable Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis [DETECT]) evaluated screening echocardiography in 466 patients with SSc at increased risk of PAH (SSc for &gt;3 years and a DLCO &lt;60 percent predicted) [<a href="#rid8">8</a>]. All patients underwent an RHC. An algorithm based on these observations accurately identified 62 percent of patients who needed RHC and indicated a PAH prevalence of 19 percent in SSc.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another cohort analysis of 419 patients with SSc at risk for PAH reported that the use of echocardiography alone failed to diagnose PAH in up to 31 percent of patients, over one-half of whom were captured by PFT [<a href="#rid44">44</a>]. The combination of echocardiography and PFT improved the negative predictive value for diagnosing PAH (97 versus 87 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another cohort analysis of 195 consecutive unselected patients with SSc compared several approaches including DETECT criteria with guidelines set forth by the European Society of Cardiology (ESC)/European Respiratory Society (ESC/ERS; recommended screening echocardiography for those with a FVC/DLCO ratio &gt;1.6 and N-terminal pro-brain natriuretic peptide [NT-proBNP] twice the upper limit of normal) and echocardiography alone [<a href="#rid48">48</a>]. The approach with a highest yield was when guidelines and DETECT were implemented together (positive predictive value 23 percent) compared with DETECT (6 percent), guidelines alone (18 percent), or echocardiography alone (11 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another study compared several algorithms, DETECT, ESC/ERS, and the Australian Scleroderma Interest Group (ASIG), and did not find significant difference in the sensitivity and specificity, and the positive and negative predictive values of these approaches, although DETECT had more negative RHCs than the other methods [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up visits</strong> – During follow-up, we perform an echocardiogram every one to two years in patients who are at high risk for PAH, and/or develop new or progressive respiratory symptoms or a low DLCO over time, because long-standing disease is a risk factor for the development of SSc-PAH. As an example, in one study, 32 percent of SSc patients at risk of developing PAH who had an initial normal RHC, subsequently developed PAH [<a href="#rid51">51</a>]. In addition, although not every patient develops progressive disease, those with borderline or mild PAH have an increased risk of developing severe PAH within two years [<a href="#rid20">20,52</a>]. These data provide the rationale for yearly evaluation in most patients with clinical examination, PFT, and echocardiogram. Additional prospective studies are needed to confirm that standard echocardiography is the appropriate guide to treatment decisions compared with repeated RHC [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">The patients with SSc who are at highest risk for the development of PAH during follow-up are those with exercise-induced PAH on stress echocardiography or RHC [<a href="#rid6">6,51,54</a>]. These issues are discussed below. (See <a class="local">'Echocardiography'</a> below and <a class="local">'Right heart catheterization'</a> below.)</p><p></p><p class="headingAnchor" id="H436387"><span class="h2">Echocardiography</span><span class="headingEndMark"> — </span>Echocardiography is the most widely used noninvasive tool for the identification of SSc-PAH. Two-dimensional echocardiography assesses right ventricle (RV) function. RV dysfunction has a wide variety of etiologies, of which PH is the most common  (<a class="graphic graphic_table graphicRef90802" href="/d/graphic/90802.html" rel="external">table 3</a>). Doppler echocardiography is useful because it estimates tricuspid regurgitant jet velocity (TR jet), which is an estimate of the right ventricular systolic pressure (eRSVP)/pulmonary artery systolic pressure (ePASP). Although, exercise echocardiography (EE) detects exercise-induced PH, its use for screening for PAH in patients with SSc remains largely investigational. (See  <a class="medical medical_review" href="/d/html/5319.html" rel="external">"Transthoracic echocardiography: Normal cardiac anatomy and tomographic views"</a> and  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Echocardiography'</a> and  <a class="medical medical_review" href="/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Evaluation for suspected systemic sclerosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Doppler echocardiography – Several studies of patients with SSc with and without known risk factors for PAH have reported rates of elevated ePASP ranging from 11 to 14 percent [<a href="#rid4">4,5</a>]. However, false positives and in particular, false negatives, exist such that cases of PAH can be missed when echocardiography is used alone for screening [<a href="#rid44">44</a>]. In addition, estimates of TR jet velocity are hampered by high-interobserver variability and poor standardization of threshold cutoff values above and below which PH should be suspected or is unlikely [<a href="#rid2">2</a>]. Suggested values of TR jet velocity and ePASP for probable or likely PH based upon expert opinion are listed in the table  (<a class="graphic graphic_table graphicRef120360" href="/d/graphic/120360.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/83974.html" rel="external">"Echocardiographic assessment of the right heart"</a> and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Echocardiography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exercise echocardiography (EE) – EE has been used to screen patients for exercise PH [<a href="#rid3">3,6,55,56</a>]. A change in ePASPs with exercise &gt;18 mmHg was reported in one study to predict the development of PH (not necessarily PAH) during follow-up (hazard ratio 3.4) [<a href="#rid6">6</a>].A study of 54 patients with SSc at risk for the development of PAH reported that 44 percent had a ≥20 mmHg increase of the ePASP during exercise, 81 percent of which had RHC-confirmed resting or exercise-induced PAH [<a href="#rid3">3</a>]. In several studies the abnormal exercise response correlated with abnormal lung function, presence of ILD, greater age, and cardiac dysfunction, suggesting that exercise-induced increases in ePASP in SSc are multifactorial and not specific for SSc-PAH [<a href="#rid3">3,55</a>]. In another four-year study of patients with SSc who did not have PAH on initial echocardiography, pulmonary exercise hemodynamics deteriorated over time but only 3 percent developed actual PAH [<a href="#rid56">56</a>]. A prospective, observational cohort of 85 patients found that a positive EE may predict the future development of resting PH. However, a majority of patients had persistently positive EE without progression to resting PH [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/d/html/5310.html" rel="external">"Overview of stress echocardiography", section on 'Doppler imaging'</a>.)</p><p></p><p class="headingAnchor" id="H11875344"><span class="h2">Right heart catheterization</span><span class="headingEndMark"> — </span>The workup for suspected PAH in patients with SSc is the same as for other types of PAH, and RHC remains the diagnostic gold standard if SSc–PAH is suspected based on the following features:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms and/or signs of PH – Although patients in whom PH is suspected may proceed directly to RHC, we typically perform an echocardiogram prior to catheterization to evaluate for cardiac causes of PH and evaluate the function of the right ventricle and tricuspid valve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An echocardiogram with evidence of PH (eg, right ventricular dysfunction, an elevated TR jet, or an increased estimated pulmonary arterial systolic pressure at rest or with exercise). (See  <a class="medical medical_review" href="/d/html/83974.html" rel="external">"Echocardiographic assessment of the right heart"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A low threshold for repeating an RHC is required in patients with exercise-induced PAH at initial RHC.</p><p></p><p>The diagnosis of PAH in SSc is confirmed when the mean pulmonary artery pressure (PAP) is greater than 20 mmHg at rest (measured by RHC), pulmonary capillary wedge pressure is less than or equal to 15 mmHg, and peripheral pulmonary vascular resistance is ≥2 Wood units in a patient without other etiologies for PH [<a href="#rid1">1</a>]. At the time of RHC, severity of PH and, in some cases, acute responsiveness to vasodilators (which is rare), are measured to guide treatment choices. Suspected SSc-PAH should not be treated without first performing a RHC, preferably in a specialized center with cardiologists and pulmonologists who have expertise in PH. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Initial diagnostic evaluation (noninvasive testing)'</a> and  <a class="medical medical_review" href="/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Pulmonary vascular disease'</a>.)</p><p class="headingAnchor" id="H1771354179"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115503.html" rel="external">"Society guideline links: Pulmonary hypertension in adults"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary hypertension (PH) is a significant complication of systemic sclerosis (SSc) and a leading cause of SSc-related death. PH is classified into five groups  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>). SSc is most often associated with group 1 pulmonary arterial hypertension (PAH) and group 3 PH (due to interstitial lung disease [ILD]), and less commonly with group 2 PH (due to left-sided heart failure). (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is defined as a mean pulmonary artery pressure (PAP) &gt;20 mmHg at rest (measured by right heart catheterization [RHC]), pulmonary capillary wedge pressure ≤15 mmHg, and peripheral pulmonary vascular resistance ≥2 Wood units in a patient who has SSc without other causes of PH. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of unrecognized PAH among patients with SSc is in the range of 10 to 15 percent. Important risk factors include long-standing limited cutaneous SSc (lcSSc), a low (&lt;80 percent predicted) or progressive decline in the diffusion capacity for carbon monoxide (DLCO), and/or a high forced vital capacity (FVC)/DLCO ratio (FVC/DLCO &gt;1.6). Other risk factors are listed in the table  (<a class="graphic graphic_table graphicRef93544" href="/d/graphic/93544.html" rel="external">table 2</a>). (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with SSc should be evaluated for PAH at initial presentation and throughout the course of their disease (see <a class="local">'Screening'</a> above and  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Evaluation for lung disease at time of SSc presentation'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients should be evaluated for the signs and/or symptoms of PAH (eg, dyspnea, syncope, signs of right heart failure, loud pulmonic second heart sound [P2]) at each visit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients should have full pulmonary function testing (PFTs; spirometry, lung volumes, and diffusing capacity) at the initial visit and annual PFTs (spirometry and DLCO) thereafter. We decrease the frequency of PFTS to every two years in patients with long-standing SSc (&gt;5 years) who are asymptomatic, a normal DLCO and have stable PFTs (&gt;3 years).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We perform echocardiography in patients who have symptoms of PAH, and in asymptomatic patients who are at significantly increased risk for PAH, as defined above. Additionally, we perform echocardiography when we suspect other SSc-associated complications such as constrictive cardiomyopathy or pericardial effusion. We do not advocate further evaluation for PAH in patients who do not have pulmonary symptoms and who have a normal DLCO. During follow-up, we perform an echocardiogram every one to two years in patients who are at significantly increased risk for PAH and/or develop symptoms or a low DLCO over time.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We perform a RHC for patients with SSc who show symptomatic, physiologic and/or echocardiographic evidence of PAH. Algorithms that combine clinical findings, pulmonary function testing and echocardiography in high-risk SSc patients may be used to select those appropriate for RHC (eg, DETECT).</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.</a></li><li><a class="nounderline abstract_t">Steen V, Chou M, Shanmugam V, et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest 2008; 134:146.</a></li><li><a class="nounderline abstract_t">Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52:2125.</a></li><li><a class="nounderline abstract_t">Hesselstrand R, Ekman R, Eskilsson J, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005; 44:366.</a></li><li><a class="nounderline abstract_t">Codullo V, Caporali R, Cuomo G, et al. Stress Doppler echocardiography in systemic sclerosis: evidence for a role in the prediction of pulmonary hypertension. Arthritis Rheum 2013; 65:2403.</a></li><li><a class="nounderline abstract_t">Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52:3792.</a></li><li><a class="nounderline abstract_t">Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73:1340.</a></li><li><a class="nounderline abstract_t">Yang X, Mardekian J, Sanders KN, et al. Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol 2013; 32:1519.</a></li><li><a class="nounderline abstract_t">Muangchan C, Canadian Scleroderma Research Group, Baron M, Pope J. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol 2013; 40:1545.</a></li><li><a class="nounderline abstract_t">Schachna L, Wigley FM, Chang B, et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003; 124:2098.</a></li><li><a class="nounderline abstract_t">Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088.</a></li><li><a class="nounderline abstract_t">Morrisroe K, Huq M, Stevens W, et al. Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC Pulm Med 2016; 16:134.</a></li><li><a class="nounderline abstract_t">Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940.</a></li><li><a class="nounderline abstract_t">Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81:139.</a></li><li><a class="nounderline abstract_t">Chung L, Domsic RT, Lingala B, et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken) 2014; 66:489.</a></li><li><a class="nounderline abstract_t">Lefèvre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 2013; 65:2412.</a></li><li><a class="nounderline abstract_t">Hinchcliff M, Fischer A, Schiopu E, et al. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011; 38:2172.</a></li><li><a class="nounderline abstract_t">Avouac J, Airò P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37:2290.</a></li><li><a class="nounderline abstract_t">Chang B, Schachna L, White B, et al. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33:269.</a></li><li><a class="nounderline abstract_t">Scorza R, Caronni M, Bazzi S, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002; 966:238.</a></li><li><a class="nounderline abstract_t">Cox SR, Walker JG, Coleman M, et al. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005; 35:28.</a></li><li><a class="nounderline abstract_t">Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35:35.</a></li><li><a class="nounderline abstract_t">Hunzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008; 47:1185.</a></li><li><a class="nounderline abstract_t">Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol 2010; 37:98.</a></li><li><a class="nounderline abstract_t">Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48:516.</a></li><li><a class="nounderline abstract_t">Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58:284.</a></li><li><a class="nounderline abstract_t">Iudici M, van der Goes MC, Valentini G, Bijlsma JW. Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review. Clin Exp Rheumatol 2013; 31:157.</a></li><li><a class="nounderline abstract_t">Kampolis C, Plastiras S, Vlachoyiannopoulos P, et al. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis. Scand J Rheumatol 2008; 37:278.</a></li><li><a class="nounderline abstract_t">Steen VD, Lucas M, Fertig N, Medsger TA Jr. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol 2007; 34:2230.</a></li><li><a class="nounderline abstract_t">Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60:1112.</a></li><li><a class="nounderline abstract_t">Assous N, Allanore Y, Batteux F, et al. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 2005; 23:199.</a></li><li><a class="nounderline abstract_t">Marie I, Jouen F, Hellot MF, Levesque H. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 2008; 158:141.</a></li><li><a class="nounderline abstract_t">Pasarikovski CR, Granton JT, Roos AM, et al. Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2016; 18:30.</a></li><li><a class="nounderline abstract_t">Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179:151.</a></li><li><a class="nounderline abstract_t">Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010; 35:95.</a></li><li><a class="nounderline abstract_t">Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther 2012; 14:R143.</a></li><li><a class="nounderline abstract_t">Hummers LK, Hall A, Wigley FM, Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol 2009; 36:576.</a></li><li><a class="nounderline abstract_t">Meune C, Avouac J, Airò P, et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 2011; 63:2790.</a></li><li><a class="nounderline abstract_t">Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63:3522.</a></li><li><a class="nounderline abstract_t">Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182:252.</a></li><li><a class="nounderline abstract_t">Khanna D, Gladue H, Channick R, et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 2013; 65:3194.</a></li><li><a class="nounderline abstract_t">Fischer A, Bull TM, Steen VD. Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken) 2012; 64:303.</a></li><li><a class="nounderline abstract_t">Gladue H, Steen V, Allanore Y, et al. Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts. J Rheumatol 2013; 40:1706.</a></li><li><a class="nounderline abstract_t">Avouac J, Huscher D, Furst DE, et al. Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. Ann Rheum Dis 2014; 73:191.</a></li><li><a class="nounderline abstract_t">Khanna D, Tan M, Furst DE, et al. Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative. Clin Exp Rheumatol 2014; 32:S.</a></li><li><a class="nounderline abstract_t">Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167:735.</a></li><li><a class="nounderline abstract_t">Vandecasteele E, Drieghe B, Melsens K, et al. Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. Eur Respir J 2017; 49.</a></li><li><a class="nounderline abstract_t">Young A, Moles VM, Jaafar S, et al. Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. Arthritis Rheumatol 2021; 73:1731.</a></li><li><a class="nounderline abstract_t">Hao Y, Thakkar V, Stevens W, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2015; 17:7.</a></li><li><a class="nounderline abstract_t">Bae S, Saggar R, Bolster MB, et al. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis 2012; 71:1335.</a></li><li><a class="nounderline abstract_t">MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40:453.</a></li><li><a class="nounderline abstract_t">Bournia VK, Tsangaris I, Rallidis L, et al. Cardiac Catheterization versus Echocardiography for Monitoring Pulmonary Pressure: A Prospective Study in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Diagnostics (Basel) 2020; 10.</a></li><li><a class="nounderline abstract_t">Valerio CJ, Schreiber BE, Handler CE, et al. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum 2013; 65:1074.</a></li><li><a class="nounderline abstract_t">Gargani L, Pignone A, Agoston G, et al. Clinical and echocardiographic correlations of exercise-induced pulmonary hypertension in systemic sclerosis: a multicenter study. Am Heart J 2013; 165:200.</a></li><li><a class="nounderline abstract_t">Kovacs G, Avian A, Wutte N, et al. Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study. Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">Quinn KA, Wappel SR, Kuru T, Steen VD. Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-risk Cohort of Patients with Systemic Sclerosis. J Rheumatol 2020; 47:708.</a></li></ol></div><div id="topicVersionRevision">Topic 8251 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36017548" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18403670" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15986394" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561735" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23754201" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Stress Doppler echocardiography in systemic sclerosis: evidence for a role in the prediction of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16320330" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687283" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23780636" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23858045" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14665486" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Age and risk of pulmonary arterial hypertension in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583573" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27677579" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329309" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Changes in causes of death in systemic sclerosis, 1972-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889413" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23983198" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23740572" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844142" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20810505" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16465657" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114278" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15667465" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Isolated pulmonary hypertension in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16084222" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Autoantibodies in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18515867" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19955048" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12571862" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18163505" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23910618" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18612928" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17937469" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19333934" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Anti-U3 RNP autoantibodies in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15895890" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18028496" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26819137" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18931333" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643943" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22691291" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19228661" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Abnormalities in the regulators of angiogenesis in patients with scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21547892" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21769843" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20339143" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24022584" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22076819" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Practical approach to screening for scleroderma-associated pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23950183" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23349131" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24295227" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480614" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28495691" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33760392" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25596924" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22307943" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11312386" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31963800" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cardiac Catheterization versus Echocardiography for Monitoring Pulmonary Pressure: A Prospective Study in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23280155" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23351823" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical and echocardiographic correlations of exercise-induced pulmonary hypertension in systemic sclerosis: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28705939" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31732551" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-risk Cohort of Patients with Systemic Sclerosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
